Why Choose Us for Multiple Myeloma Treatment
The Huntsman Cancer Institute Multiple Myeloma and Plasma Cell Disorders Care Team provides personalized, state-of-the-art care with compassion and expertise. We are dedicated to offering our patients the highest quality of clinical trial options and are continually working in the lab to identify breakthrough immunotherapies through cutting-edge research.
“Coming here was a lifesaver. Everyone connects with you on a personal level.”
Jeannette Nielsen
Multiple myeloma patient
Specialized Treatments
Our Plasma Cell Dyscrasias Program provides care for people with a wide range of hematologic diseases including multiple myeloma, smoldering myeloma, monoclonal gammopathy of undetermined and clinical significance, AL amyloidosis, and Waldenström macroglobulinemia. We offer monitoring and treatment for these plasma cell disorders from commercially available modalities to Phase 1, 2, and 3 clinical trials.
We work with each of our patients to tailor their treatment to both their personal needs and the requirements of their disease state and stage. Our treatments include the following:
- Immunotherapy
- CAR-T Cell (chimeric antigen receptor T cell)
- T-cell redirecting bispecific antibodies (bispecifics)
- Monoclonal antibodies
- Novel therapeutic agents
- Chemotherapy
- Stem cell transplant
- Radiation therapy
- Integrative wellness, including dietary, exercise, and other lifestyle interventions and education
Bispecific Collaborative Access and Referral Network
The Huntsman Cancer Institute Bispecific Collaborative Access and Referral Network (HCI biCARE) is designed to increase patient access to bispecific antibodies (BsAbs), especially for patients with multiple myeloma in rural areas of the Mountain West. We offer education and support to community health providers and affiliate networks to eliminate barriers to drug access and improve patient outcomes.
Our Expertise
Our Plasma Cell Dyscrasia Program currently includes five dedicated physicians, five advanced practice clinicians (APCs), a support staff of more than 40 others, as well as a dedicated plasma cell disorder scientific team working on drug development and immune profiling. As an organization, we see close to 8,000 patient visits each year and have doubled our clinical volumes and trial accruals in just the past two years.
This is a modal window.
Message from Our Director
“We aim to create an environment where our patients feel comfortable and taken care of, where we consider your emotional and physical needs in addition to treating cancer. We understand the difficulties associated with this disease and we are here to help you and your family navigate the cancer journey.”
Douglas W. Sborov, MD, MS
Director, Multiple Myeloma program
Patient Care Philosophy
We believe no one should face cancer alone. Our dedicated and world-renowned doctors, nurses, and medical staff are at the forefront of patient-centered care. We treat the whole person, not just their cancer.
Each day, our medical, surgical, and radiation oncologists work together across disciplines to create and coordinate treatment plans for every patient. We understand cancer is a complex disease. That is why we use a team approach that includes social workers and support groups, as well as wellness and integrative health services such as acupuncture, massage, creative arts, and more.
Find a Multiple Myeloma Provider
Multiple Myeloma Research
At Huntsman Cancer Institute, research is critical to our mission of better understanding, treating, and preventing cancer. We have programs supported by the National Cancer Institute that focus on laboratory, clinical, and population-based studies. We also have specialty Disease Centers that serve as collaborative hubs where doctors and scientists share findings and work together to accelerate progress.
Our scientists study the biology of cancer, explore the promise of immunotherapy, and find new ways to treat people using personalized medicine. We have made significant discoveries about genes linked to cancer risk, and our experts train the next generation of cancer researchers to make a difference in cancer care.
In addition, clinical trials test new drugs, drug combinations, procedures, and processes. These are key to improving cancer prevention, diagnosis, and care. Patients on clinical trials may receive access to cutting-edge therapies not yet widely available, with studies being closely monitored so patient well-being is always the top priority. Our goal is to find new cancer treatments and improve the quality of life for people with cancer.
Clinical Trials
Make an Appointment with a Multiple Myeloma Specialist
To make an appointment with a multiple myeloma specialist, fill out our appointment form or call 801-587-7000. Our team will determine if your insurance covers treatment at Huntsman Cancer Institute or if you need a referral from a primary care doctor.
External providers can refer a patient using the online referral form or by calling 801-587-7000 to speak to a patient registration specialist.
Multiple Myeloma Basics
Multiple myeloma is a type of blood cancer that originates in plasma cells, which are a type of white blood cell found in the bone marrow. Plasma cells are responsible for producing antibodies, which help the immune system fight infections. In multiple myeloma, these cells become abnormal and multiply uncontrollably, leading to the production of defective antibodies (known as M proteins or monoclonal proteins) and crowding out normal blood cells.
This abnormal cell growth disrupts various bodily processes, causing symptoms such as bone pain, frequent infections, anemia, kidney issues, and high blood calcium levels. The condition is generally more common in older adults and has no known cure, though treatments like chemotherapy, immunotherapy, and targeted therapy can help manage symptoms, slow disease progression, and improve quality of life.
Early diagnosis is essential, but multiple myeloma can be challenging to detect because its symptoms often resemble other conditions. Blood tests, bone marrow biopsies, and imaging studies are commonly used to confirm a diagnosis.
Related News and Stories
Featured Patient Story
This is a modal window.
